This drug has been developed in the United States.
Washington: Dengue fever, a mosquito-borne disease, remains a significant health concern in various regions of Pakistan.
It often presents flu-like symptoms, including high fever, and can escalate to severe conditions, including bleeding and even death.
While there is currently no cure for dengue, doctors can manage its symptoms to some extent.
However, a recent clinical trial has offered promising results for a potential treatment for the disease.
Developed in the United States by Johnson & Johnson, this experimental drug was tested on a small group of people.
Ten healthy participants were recruited and administered high doses of the drug for five days before being exposed to the dengue virus.
After the virus injection, the drug was continued for an additional 21 days.
The results were encouraging. Among the ten participants, six showed no detectable dengue virus in their blood, and no signs of virus infection were observed during 85 days of monitoring.
It's important to note that the individuals were exposed to a weakened version of the virus.
Researchers are now preparing for the second phase of clinical trials, which will evaluate the drug's effectiveness against four different strains of the dengue virus.
Following these trials, the drug may move closer to becoming an approved treatment.
The drug works by blocking two viral proteins, preventing the virus from replicating, and has shown a favorable safety profile in trial participants.
Eight policemen, driver killed in Maoist attack in central India
- 8 hours ago
PM orders strict legal action against all human trafficking groups, confiscation of properties
- 5 hours ago
Jackson focus on playoffs after Ravens win North
- 8 hours ago
Trump and Musk actually made a good point on immigration
- 9 hours ago
Garrett: Browns' '24 more disappointing than 0-16
- 8 hours ago
Shan Masood keeps South Africa at bay as Pakistan continue fight in second Test
- 7 hours ago